Cadonilimab in Combination With Chemotherapy for Locally Advaced Esophageal Squamous Cell Carcinoma

Inclusion Criteria: * Age 18-70 years, both men and women * Pathologically confirmed esophageal squamous cell carcinoma，and the clinic staging is cT2N1-3M0 or cT3N0-3M0 or cT4N0-3M0, TNM staging is II-IVA * Non-cervical esophageal carcinoma * Patients who have never received systemic antitumor therapy and who have measurable lesions that meet RECIST 1.1 criteria * ECOG score 0-1 * Life expectancy ≥12 months * Patients with normal function organs, no serious abnormalities of blood, heart, lung, liver, kidney function, and immunodeficiency disease * For female subjects of childbearing age, they should have a negative urine or serum pregnancy test within 7 days before receiving the first study drug administration. Male and female patients need to use high-efficiency contraception during treatment until at least 8 weeks after stop the treatment * Sign the informed consent form before any trial-related procedures are implemented Exclusion Criteria: * -Other malignancies diagnosed within 5 years prior to the first administration of the study drug, except effectively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or effectively resected in situ cervical and/or breast cancer * ulcerative esophageal squamous cell carcinoma * Esophageal or tracheal fistula * History of allergy to study drug components * History of immune disease * Patients with any serious or uncontrolled systemic disease * The presence of any adverse event (CTCAE\>grade 1) caused by prior therapy